Ray Chacko

Suggest Changes
Learn More
This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer. We also examined gene expression profiles from tumour(More)
CONTEXT Patients with advanced cancer may develop severe physical and psychosocial symptoms. There are limited data on the impact of an outpatient palliative consultation (PC) team on cancer-related(More)
4550 Background: Tivozanib is a potent and selective small molecule tyrosine kinase inhibitor (TKI) of VEGFR-1, -2, and -3. METHODS Patients (pts) with advanced RCC (all histologies) and no prior(More)
5032 Background: AV-951 is a potent inhibitor of VEGFR-1, 2 & 3 kinases (IC50 0.21, 0.16 and 0.24 nM respectively), and inhibits cKit and PDGFR at 10-times higher concentrations (IC50 1.63 and 1.72(More)